Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SOPHiA GENETICS (SOPH) Common Equity (2020 - 2025)

SOPHiA GENETICS's Common Equity history spans 6 years, with the latest figure at $47.1 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 51.14% to $47.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $47.1 million, a 51.14% decrease, with the full-year FY2025 number at $47.1 million, down 51.14% from a year prior.
  • Common Equity hit $47.1 million in Q4 2025 for SOPHiA GENETICS, down from $60.7 million in the prior quarter.
  • Over the last five years, Common Equity for SOPH hit a ceiling of $289.7 million in Q3 2021 and a floor of $47.1 million in Q4 2025.
  • Historically, Common Equity has averaged $153.8 million across 5 years, with a median of $151.4 million in 2023.
  • Biggest five-year swings in Common Equity: surged 220.86% in 2022 and later tumbled 51.14% in 2025.
  • Tracing SOPH's Common Equity over 5 years: stood at $275.4 million in 2021, then decreased by 27.33% to $200.1 million in 2022, then fell by 24.33% to $151.4 million in 2023, then crashed by 36.29% to $96.5 million in 2024, then plummeted by 51.14% to $47.1 million in 2025.
  • Business Quant data shows Common Equity for SOPH at $47.1 million in Q4 2025, $60.7 million in Q3 2025, and $76.7 million in Q2 2025.